From the NY Times today, below is the new list for negotiated drugs prices for Medicare plans by the federal government. Several are for lungs.
I have not included the full article as the rhetoric is full of political quotes that I find to be unproductive.
I have found, after the first round of drugs negotiated, that thanks to the pharmacy benefit managers, they are keeping their profits by increasing the drug plan premiums, changing the tier that determines the drug cost, and other maneuvers. Overall, the effect is that consumers are not really saving money. The number of plans offered has also decreased with insurers dropping out.
Prices for Drugs in Medicare’s Second Round of Negotiations
Prices are the maximum Medicare Part D plans, and the patient will pay for a one-month supply. Prices will take effect in 2027.
1. Ozempic and Rybelsus, for diabetes, $277; Wegovy, for obesity, $386
2. Trelegy Ellipta, for lung conditions, $175
3. Xtandi, for prostate cancer, $7,004
4. Pomalyst, for blood cancer, $8,650
5. Ibrance, for breast cancer, $7,871
6. Ofev, for lung conditions, $6,350
7. Linzess, for gastrointestinal conditions, $136
8. Calquence, for blood cancers, $8,600
9. Austedo and Austedo XR, for neurological diseases, $4,093
10. Breo Ellipta, for lung conditions, $67
11. Tradjenta, for diabetes, $78
12. Xifaxan, for liver and gastrointestinal problems, $1,000
13. Vraylar, for depression, $770
14. Janumet and Janumet XR, for diabetes, $80
15. Otezla, for inflammatory conditions, $1,650
END